Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger(The University of Texas MD Anderson Cancer Center), Thomas J. Kipps(University of California San Diego), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Michael O’Dwyer(Ollscoil na Gaillimhe – University of Galway), Steven Coutré(Georgetown University), Fong Clow(Pharmacyclics (United States)), Deepali Suri(Pharmacyclics (United States)), Don A. Stevens(Norton Healthcare), Constantine S. Tam(The Alfred Hospital), David Simpson(North Shore Hospital), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Jiřı́ Mayer(Masaryk University), Paul M. Barr(University of Rochester Medical Center), Osnat Bairey(Tel Aviv University), Carolyn Owen(University of Calgary), Sebastian Grosicki(Medical University of Silesia), Ann Janssens, Anna Schuh(University of Oxford), Nancy L. Bartlett(Washington University in St. Louis), Helen O. McCarthy(Queen's University Belfast), Danelle F. James(Pharmacyclics (United States)), Stephen Devereux, Tadeusz Robak(Medical University of Lodz), Paolo Ghia(Vita-Salute San Raffaele University), Hang Quach(The University of Melbourne), Jianyong Li(Jiangsu Province Hospital), Mei Cheng(Pharmacyclics (United States)), Aaron Polliack(Hadassah Medical Center), Lori Styles(Vyne Therapeutics (United States)), Andrzej Hellmann(Gdańsk Medical University), Tanya Siddiqi(City Of Hope National Medical Center), Fritz Offner(Ghent University Hospital), Zvenyslava Maslyak(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine)
New England Journal of Medicine
December 6, 2015
Cited by 1,558


Related Papers